Novo Nordisk's diabetes and weight loss drug, Ozempic, may have potential to help break addictions, according to The Guardian. Users have reported a decrease in addictive behaviors, such as smoking and drinking, while on the medication. Early studies have shown that semaglutide, the scientific name for Ozempic, seems to reduce binge drinking in rodents, and previous generations of GLP-1 drugs have been associated with reduced consumption of nicotine, cocaine, and opioids. Clinical trials are underway to determine whether semaglutide can help smokers and people with alcohol use disorder reduce their intake.